Merck Singulair launched in U.K. at price of $1.50 per day; U.S. review deadline is Feb. 21.

MERCK SINGULAIR ADD-ON ASTHMA THERAPY INDICATION IN EUROPE allows use of the once-a-day oral leukotriene receptor antagonist "in the treatment of asthma as add-on therapy in those patients with mild to moderate asthma who are inadequately controlled on inhaled corticosteroids and in whom `as-needed' short acting ~-agonists provide inadequate clinical control of asthma," the European summary of product characteristics reads. Merck launched Singulair (montelukast) in the U.K. Feb. 4. The product's approval is pending at FDA with a user fee review deadline of Feb. 21.